HAVCR2 expression
|
RCC
|
HAVCR2 expression
|
RCC
|
nivolumab + ipilimumab Sensitive: C3 – Early Trials
|
nivolumab + ipilimumab Sensitive: C3 – Early Trials
|
HAVCR2 expression
|
RCC
|
HAVCR2 expression
|
RCC
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
HAVCR2 expression
|
Follicular Lymphoma
|
HAVCR2 expression
|
Follicular Lymphoma
|
venetoclax + atezolizumab + obinutuzumab Sensitive: C3 – Early Trials
|
venetoclax + atezolizumab + obinutuzumab Sensitive: C3 – Early Trials
|
HAVCR2 expression
|
Nasopharyngeal Carcinoma
|
HAVCR2 expression
|
Nasopharyngeal Carcinoma
|
PDR001 Sensitive: C3 – Early Trials
|
PDR001 Sensitive: C3 – Early Trials
|
HAVCR2 expression
|
AML
|
HAVCR2 expression
|
AML
|
avelumab Resistant: D – Preclinical
|
avelumab Resistant: D – Preclinical
|